NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
Clinical Trials
11 trialsNCT02101736 2023-05-24
NF105-CABO
University of Alabama at Birmingham
Phase 2 Completed
NCT02471339 2022-06-14
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00727233 2019-12-12
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00076102 2018-04-23
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00396019 2017-11-06
Study of PEG-Intron for Plexiform Neurofibromas
University of Pittsburgh
Phase 2 Completed
NCT01275586 2017-04-12
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Indiana University
Phase EARLY_PHASE1 Completed
NCT00053937 2015-04-30
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
National Cancer Institute (NCI)
Phase 1 Completed
NCT01412892 2014-11-14
NFitor
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT00754780 2012-03-19
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
Mayo Clinic
Phase 2 Completed